WO2008114577A2 - Peptide antibactérien - Google Patents

Peptide antibactérien Download PDF

Info

Publication number
WO2008114577A2
WO2008114577A2 PCT/JP2008/053211 JP2008053211W WO2008114577A2 WO 2008114577 A2 WO2008114577 A2 WO 2008114577A2 JP 2008053211 W JP2008053211 W JP 2008053211W WO 2008114577 A2 WO2008114577 A2 WO 2008114577A2
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
integer
gly
amino acid
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/053211
Other languages
English (en)
Japanese (ja)
Other versions
WO2008114577A3 (fr
Inventor
Masao Tanihara
Keiko Ida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nara Institute of Science and Technology NUC
PHG Corp
Original Assignee
Nara Institute of Science and Technology NUC
PHG Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nara Institute of Science and Technology NUC, PHG Corp filed Critical Nara Institute of Science and Technology NUC
Priority to JP2009505105A priority Critical patent/JP5354206B2/ja
Publication of WO2008114577A2 publication Critical patent/WO2008114577A2/fr
Publication of WO2008114577A3 publication Critical patent/WO2008114577A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne un peptide présentant une sécurité élevée et une activité antibactérienne excellente, ou un sel de ce peptide. Plus précisément, l'invention concerne un peptide choisi parmi les peptides suivants (1) et (2) ou un sel dudit peptide: (1) un peptide comprenant une séquence d'acides aminés représentée par la formule générale (I) (Pro Hyp Gly)n-[(Lys x Gly)m-(Pro Hyp Gly)l-(Lys X Gly)p]α- (Pro Hyp Gly)r (I) [dans laquelle n représente un entier compris entre 1 et 6; m un entier compris entre 1 et 4; l un entier compris entre 0 et 7; p un entier compris entre 1 et 4; r un entier compris entre 1 et 6; α un entier compris entre 1 et 6; et X un résidu d'acides aminés choisi parmi Ile, Leu et Hyp, pour autant que les pièces (m+p) de X puissent être identiques ou différentes les unes des autres, n+m+l+p+r = 4 à 15, m+p≥2 lorsque l=0, et m=1, l=0 et p=1 lorsque α≥2.]; (2) un peptide comprenant une séquence d'acides aminés ayant la substitution, la suppression ou l'addition de 1 à 3 résidus d'acides aminés autres que Lys, Gly et X dans la séquence d'acides aminés représentée par la formule (I) et possédant une activité antibactérienne.
PCT/JP2008/053211 2007-02-26 2008-02-25 Peptide antibactérien Ceased WO2008114577A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009505105A JP5354206B2 (ja) 2007-02-26 2008-02-25 抗菌性ペプチド

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007045490 2007-02-26
JP2007-045490 2007-02-26

Publications (2)

Publication Number Publication Date
WO2008114577A2 true WO2008114577A2 (fr) 2008-09-25
WO2008114577A3 WO2008114577A3 (fr) 2008-11-27

Family

ID=39766594

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/053211 Ceased WO2008114577A2 (fr) 2007-02-26 2008-02-25 Peptide antibactérien

Country Status (2)

Country Link
JP (1) JP5354206B2 (fr)
WO (1) WO2008114577A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013111759A1 (fr) * 2012-01-23 2013-08-01 学校法人早稲田大学 Peptide de type collagène ayant une propriété de furtivité et une propriété d'excrétion urinaire élevée
CN110079531A (zh) * 2019-04-26 2019-08-02 安阳工学院 一种抗菌肽及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11215983A (ja) * 1998-01-30 1999-08-10 Agriculture Forestry And Fisheries Technical Information Society ペプチドを有効成分とする抗真菌剤
JP4037525B2 (ja) * 1998-03-25 2008-01-23 生化学工業株式会社 新規抗菌性ペプチド
JP3488133B2 (ja) * 1999-05-14 2004-01-19 明治乳業株式会社 抗菌性ペプチド
JP5070442B2 (ja) * 2002-02-28 2012-11-14 株式会社Ｐｈｇ 新規なポリペプチドおよびその製造方法
JP2005060550A (ja) * 2003-08-13 2005-03-10 Masao Tanihara 被膜形成組成物
JP4303137B2 (ja) * 2004-01-23 2009-07-29 株式会社Ｐｈｇ 新規なポリペプチド及びその製造方法
US7452856B2 (en) * 2004-07-06 2008-11-18 Seikagaku Corporation Antibacterial peptide
EP1908828A1 (fr) * 2005-07-22 2008-04-09 PHG Corporation Nouveau polypeptide et procede servant a produire celui-ci

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013111759A1 (fr) * 2012-01-23 2013-08-01 学校法人早稲田大学 Peptide de type collagène ayant une propriété de furtivité et une propriété d'excrétion urinaire élevée
CN110079531A (zh) * 2019-04-26 2019-08-02 安阳工学院 一种抗菌肽及其应用
CN110079531B (zh) * 2019-04-26 2022-09-20 安阳工学院 一种抗菌肽及其应用

Also Published As

Publication number Publication date
JPWO2008114577A1 (ja) 2010-07-01
WO2008114577A3 (fr) 2008-11-27
JP5354206B2 (ja) 2013-11-27

Similar Documents

Publication Publication Date Title
NZ598356A (en) Antigenic tau peptides and uses thereof
MXPA06001283A (es) Derivados de insulina novedosos.
JP2013511554A5 (fr)
GB2431404A (en) Peptide
WO2007056362A3 (fr) Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees
HRP20161614T1 (hr) Terapijska sredstva za smanjenje razina paratiroidnog hormona
NZ601175A (en) Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
DK2162462T3 (da) Cxc-chemokin-receptor-4 (cxcr4) antagonistisk polypeptid
MX2011011960A (es) Peptidos penetradores de celulas.
WO2013003045A3 (fr) Peptides procoagulants et leurs dérivés et leurs utilisations
WO2009155257A8 (fr) Analogues de glucagon présentant des tampons de ph physiologique présentant une solubilité et une stabilité améliorées
WO2008086086A3 (fr) Analogues de glucagon présentant une solubilité améliorée dans des tampons à ph physiologiques
WO2005023866A3 (fr) Peptides permettant d'inhiber l'activation du complement
WO2009025117A1 (fr) Peptide cdca1 et agent pharmaceutique le comprenant
WO2008057463A3 (fr) Conditionneurs à base de peptides
WO2011038900A3 (fr) Analogues peptidiques de glucagon pour une thérapie du diabète
PH12012502372A1 (en) Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
CA2651990C (fr) Peptides antimicrobiens ameliores
WO2007149542A3 (fr) Compositions de chémokine microbicide antimicrobiennes et procédés d'utilisation
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
ATE482978T1 (de) Mimetische cd4-peptide und ihre verwendungen
WO2009025116A1 (fr) Peptide cdh3 et agent médicinal le comprenant
WO2007076162A3 (fr) Peptides antimicrobiens de cathelicidine
EA201100459A1 (ru) Композиции, включающие интерлейкин-1 и пептиды

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08711940

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009505105

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08711940

Country of ref document: EP

Kind code of ref document: A2